The three drug discovery deals are with Convelo Therapeutics in neurological disorders such as multiple sclerosis, Sosei Heptares for G-protein-coupled receptor-targeting compounds, and Skyhawk ...

Another company working on an RNA splicing modifier drug for Huntington's is Skyhawk Therapeutics, which reported phase 1 data with its SKY-0515 candidate earlier this year. Earlier this year ...

The Douglas Aircraft Company (now owned by Boeing) answered the Navy’s call by building the A-4 Skyhawk. Ed Heinemann, the lead designer for the A-4 Skyhawk, encapsulated the Skyhawk’s ethos ...

They are developing cutting-edge solutions in diagnostics, therapeutics, and biotechnology, including AI-powered tools, gene editing, and digital health platforms. The report highlights key ...

They are developing cutting-edge solutions in diagnostics, therapeutics, and biotechnology, including AI-powered tools, gene editing, and digital health platforms. The report highlights key startups ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

Tune Therapeutics’ co-founders, from left: Akira Matsuno, chief financial officer; Charles Gersbach; and Fyodor Urnov, who also serves on the startup’s scientific advisory board. (Tune Photos ...

The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are suffering this morning.

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...